Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449698 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EGBA1CARM1PRMT6 | |
| SCHEMBL12449700 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EGBA1CARM1PRMT6 | |
| SCHEMBL12449658 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12837 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12449655 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4ELMNAHRH3 | |
| SCHEMBL12449703 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL25662587 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL12669 | 0.88 | HRH3 (0.44) | ALDH1A1KDM4ESIGMAR1HRH3 | |
| SCHEMBL12607 | 0.87 | ALDH1A1 (0.53) | ALDH1A1KDM4ECARM1PRMT6PRMT1 | |
| SCHEMBL24494832 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4ECARM1PRMT6PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-109970708-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2022-06-21 | — | — | CN | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885KDM4E 3533/4885GBA1 460/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885KDM4E 444/4885GBA1 4369/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | ALDH1A1 297/4885KDM4E 3351/4885GBA1 2394/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885KDM4E 3533/4885GBA1 460/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | ALDH1A1 2692/4885KDM4E 3391/4885GBA1 1720/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | ALDH1A1 2692/4885KDM4E 3391/4885GBA1 1720/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885KDM4E 3533/4885GBA1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.